MDGL · Madrigal Pharmaceuticals Inc
Price
Snapshot
50 fields · last close| Market Cap | $10.58B |
| P/E | — |
| Float | 21.75M |
| Beta | -1.09 |
| Volatility | 27.3% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Large cap |
| Macro sensitivity | Low |
| Clavix score | 76.5 |
| Price | 457.42 |
| Change | −0.12% |
| Prev Close | 457.96 |
| Open | 467.90 |
| Day Low | 456.65 |
| Day High | 481.87 |
| Avg Vol | 0 |
| Avg $ Vol | $157.6M |
| 52W High | 615.00 |
| 52W Low | 393.61 |
| 52W Pos | 28.8% |
| From High | −25.62% |
| From Low | +16.21% |
| Max DD 1Y | −29.36% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | −5.17% |
| SMA 50 | −10.43% |
| SMA 200 | −9.09% |
| RSI (14) | 35.6 |
| Vol 30D | 25.4% |
| Vol 90D | 38.3% |
| 1Y Range | 394–615 |
| Daily bars | 539 |
| Perf Week | −0.45% |
| Perf Month | −11.73% |
| Perf Quarter | −15.72% |
| Perf Half Y | −13.45% |
| Perf Year | +4.09% |
| Perf YTD | −22.98% |
| Prev Day | −0.12% |
| Clavix | B |
| Debt / Eq | 0.56 |
| Curr Ratio | 4.01 |
| Int Cover | -68.3× |
| FCF Margin | −19.8% |
| Rev Growth | +432.1% |
| Profit | Unprofitable |
| Leverage | Low |
| Sector rank | 12 / 35 |
Clavix risk grade
regraded every trading dayMDGL grades B, 76.5 of 100. Steadiest on Macro Resilience (68), most exposed on Price Stability (59, mixed). 2 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 12 of 35 in Biotechnology by Clavix score.
How rough the ride is
| MDGL | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | −1.09 | 0.50 |
| Volatilityannualized | 27.3% | 14.4% |
| Max drawdown, past yearworst peak-to-trough fall | −29.4% | — |
| Typical daily movemedian absolute daily change | 1.36% | — |
| Days beyond ±3%of the last 252 sessions | 52 (21%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| MDGL | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | −1.09 | 0.50 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Low 53% of 36 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| MDGL | |
|---|---|
| 1 week | −0.4% |
| 1 month | −11.7% |
| Year to date | −23.0% |
| 1 year | +4.1% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| MDGL | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 20 Jul |
| Average score0 most bearish, 100 most bullish | 68 |
| Bullish · bearisharticles above 60 · below 40 | 25 · 0 |
| Directionarticles whose tone is improving vs worsening | 25 ↑ 0 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 36 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| MDGL | |
|---|---|
| Revenue growthyear over year | +432.1% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openMadrigal Pharmaceuticals reported Rezdiffra quarterly sales of $364.3M, up 71% from a year earlier, with more than 50,000 patients on the drug and an 89% gross margin. The company says drug revenue now covers its operating costs, recurring cash operations are roughly breaking even, and cash on the balance sheet grew, even though the headline quarter showed a loss. Market penetration is only around 11%, with key 2027 trial data still ahead.
Madrigal Pharmaceuticals released a follow-up analysis of its Phase 3 MAESTRO-NASH trial showing that Rezdiffra's liver improvements held up across several common genetic variants seen in MASH (a fatty liver disease) patients. The article also notes MDGL shares are down about 9.86% over the past month and 17.87% year to date, while the one-year total return to shareholders remains positive at 11.62%.
Madrigal Pharmaceuticals' stock is up about 500% over the past five years, and the article raises the question of whether today's share price is supported by the company's current revenue base. It points to fresh data from the MAESTRO-NASH trial analysis for Rezdiffra (MDGL's drug) as a potential support for investor expectations.
Madrigal Pharmaceuticals said a pre-specified secondary analysis of its Phase 3 MAESTRO-NASH trial, published in the Journal of Hepatology, showed its drug Rezdiffra (resmetirom) improved liver scarring, fat levels and disease markers in MASH (severe fatty liver disease) patients regardless of common genetic risk variants, with safety consistent with the overall study.
Madrigal announced that the Journal of Hepatology published a pre-specified follow-up analysis from the Phase 3 MAESTRO-NASH trial showing Rezdiffra (resmetirom), the company's MASH drug, worked consistently regardless of patients' common genetic risk variants for the disease.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| TWST | Twist Bioscience Corp | D+ | $9.88B | — | 2.18 | Compare |
| KRYS | Krystal Biotech Inc | B | $9.54B | 39.42 | 0.64 | Compare |
| CAI | Caris Life Sciences Inc | C | $9.14B | 86.95 | 0.40 | Compare |
| PTGX | Protagonist Therapeutics Inc | B | $8.93B | 109.73 | 1.19 | Compare |
| SYRE | Spyre Therapeutics Inc | — | $8.87B | — | 2.95 | Compare |
| CYTK | Cytokinetics Inc | B+ | $8.74B | — | 0.42 | Compare |
| BBIO | BridgeBio Pharma Inc | B | $13.24B | — | 0.95 | Compare |
| ARWR | Arrowhead Pharmaceuticals Inc | C+ | $8.31B | — | 1.34 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.